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Background and Aims: Although several new compounds are currently under investigation, therapy with pegylated interferonalpha-2a (Peg-IFN) is still considered the standard of care for patients
with HDV chronic hepatitis (CHD). This study investigates host and virological patterns during Peg-IFN treatment as feasible predictors of response.
Method: Eighty sequential serum samples from 16 CHD patients (HBV genotype D and HDV genotype 1)were tested. Serum HDV-RNA and HBV-DNA were detected by real-time quantitative PCR; HBsAg, HBcrAg and anti-HBc IgG levels were determined by chemiluminescence
immunoassay (LumipulseR G system, Fujirebio, Japan). Serum concentration of 12 soluble immune modulators (IL-1ra, IL2-ra, IL-6, IL-7, IL-10, IL-12p70, IL-13, IL-16, IP-10, INFgamma, TNFalfa e TNFbeta) were evaluated by LUMINEX-based multiplex technology. Virological and immunological markerswere measured at baseline, 6, 12, 18 and 12 months after end of therapy (12MFU).
Results: Overall, 8 patients cleared HDV RNA during treatment and were still negative at 12MFU (responders, R), among them 2 cleared HBsAg and 1 became anti-HBs positive. Eight patients were not responders (NR). Except anti-HBc IgG,the other virological markers HDV-RNA, HBsAg and HBcrAg showed mean baseline levels significantly lower in R then in NR (Table). By combining baseline levels and reduction values at 6 months, HDV RNA, HBsAg and HBcrAg showed a
high accuracy in distinguish R and NR (area under the curve [AUC] =0.969, 0.958, 0.891, respectively). Compared to normal physiological levels, CHD patients had lower values of IL-7 and Il-13; conversely, IP-10 levels were distinctly higher (more than ten-fold). No difference




Conclusion: Peg-IFN treatment induces in CHD patients specific cytokines response showing a modulation of the innate IFN system but not predictive of the response to therapy. Conversely, the
combination of baseline and early on-treatment 6 months values of either HDV RNA, HBsAg, HBcrAg, may be useful to predict treatment efficacy.

